Source facts
FDA issued an approval letter for TRUTAKNA on 2026-07-08. The source metadata identifies BLA 761486 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
TRUTAKNA — FDA Approval Letter (BLA 761486)
Issued to VERA THERAPEUTICS INC.. Application is approved as submitted.
Issued
July 8, 2026Application
BLA • 761486
Product
TRUTAKNA
Company
VERA THERAPEUTICS INC.
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for TRUTAKNA?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: BLA 761486.
- 3Submission: original application.
- 4Sponsor: VERA THERAPEUTICS INC..
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the TRUTAKNA approval letter
Is TRUTAKNA FDA approved?
This letter documents an FDA approval action: FDA approved BLA 761486 for TRUTAKNA, sponsored by VERA THERAPEUTICS INC., on July 8, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is BLA 761486?
BLA 761486 is the application under which FDA issued this approval letter for TRUTAKNA to VERA THERAPEUTICS INC.. The letter is dated July 8, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.